Related Experiment Video
Updated: Jun 2, 2026
10:02
Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
Published on: December 19, 2025
In-Depth Plasma Proteomics Identifies SNCA as a Discriminating Biomarker of PDAC
Jiaqi Yu1, Wenhui Luo2, Jian Zhang3,4
1School of Basic Medicine, Qingdao University, Qingdao, Shandong Province 266071, China.
Journal of Proteome Research
|June 1, 2026
Summary
Researchers developed a 5-protein blood test to detect pancreatic cancer (PDAC). The SNCA protein shows promise as a diagnostic marker, especially for patients with low CA19-9 levels.
Area of Science:
- Biochemistry
- Oncology
- Proteomics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to limited diagnostic methods.
- Early detection is crucial for improving patient outcomes in PDAC.
Purpose of the Study:
- To develop and validate a novel plasma proteome-based diagnostic model for PDAC.
- To identify specific protein biomarkers for early PDAC detection.
Main Methods:
- Mass spectrometry-based high-coverage plasma proteome analysis.
- Machine learning algorithms applied to identify a 5-protein signature (SNCA, GCLC, LBP, ALAD, SORD).
- Validation in independent cohorts, including PDAC patients with low CA19-9 levels.
Main Results:
- A 5-protein model achieved high diagnostic performance (AUC=0.973, 100% sensitivity, 85% specificity) in a discovery cohort.
- Nested cross-validation confirmed robust model performance (AUC=0.958).
- SNCA demonstrated significant diagnostic potential (AUC=0.835) in an independent cohort and in PDAC patients with low CA19-9 (AUC=0.868).
Conclusions:
- The 5-protein signature shows strong potential for PDAC diagnosis.
- SNCA is identified as a promising candidate plasma biomarker for PDAC detection.
- SNCA may be particularly valuable for diagnosing PDAC in patients with currently undetectable CA19-9 levels.
